---
title: "Tirabrutinib in Primary central nervous system lymphoma: References"
description: "Reference list for the formulary evidence report on Tirabrutinib in Primary central nervous system lymphoma. 67 cited documents."
canonical: "https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Tirabrutinib in Primary central nervous system lymphoma: References

<a id="references"></a>

## 5 References

1. [Akimoto et al. (2026)](https://www.jstage.jst.go.jp/article/nmccrj/13/0/13_2026-0112/_html/-char/en)
2. [Arakawa et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10517093/)
3. [Cayman Chemical safety data sheet (2025)](https://cdn.caymanchem.com/cdn/msds/32957m.pdf)
4. [Čermáková et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41297046/)
5. [Chen et al. (2022)](https://link.springer.com/article/10.1186/s13045-022-01356-7)
6. [Deciphera Pharmaceuticals](https://www.deciphera.com/pipeline)
7. [Deciphera Pharmaceuticals (2026)](https://www.deciphera.com/news/deciphera-pharmaceuticals-announces-us-food-and-drug-administration-acceptance-filing-new-drug)
8. [Dhillon (2020)](https://pubmed.ncbi.nlm.nih.gov/32382949/)
9. [Doolittle et al. (2013)](https://ohsu.elsevierpure.com/en/publications/long-term-cognitive-function-neuroimaging-and-quality-of-life-in--2/)
10. [FDA Orphan Drug Designations and Approvals (2023)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=930322)
11. [Ferreri et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/hem3.89)
12. [Gilead Sciences protocol GS-US-401-2076 (2019)](https://cdn.clinicaltrials.gov/large-docs/17/NCT02983617/Prot_000.pdf)
13. [Guo et al. (2024)](https://www.sciencedirect.com/science/article/pii/S1878875024006302)
14. [Hoang-Xuan et al. (2023)](https://academic.oup.com/neuro-oncology/article-abstract/25/1/37/6661445)
15. [Hsiao et al. (2026a)](https://onlinelibrary.wiley.com/doi/10.1002/cam4.71707)
16. [Hsiao et al. (2026b)](https://library.ehaweb.org/eha/2026/eha-2026/4208702/liang-tsai.hsiao.real-world.durable.clinical.benefits.of.tirabrutinib.and.its.html)
17. [Iizuka-Honma et al. (2023)](https://www.jstage.jst.go.jp/article/internalmedicine/62/3/62_9591-22/_article/-char/en)
18. [Ikegawa et al. (2025)](https://academic.oup.com/skinhd/article/5/2/151/8106519)
19. [Ishi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41243010/)
20. [Kawabata et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13556510/)
21. [Kawasaki et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12150651/)
22. [Kawauchi et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12696247/)
23. [KEGG](https://www.kegg.jp/entry/D11070)
24. [Khairunnisa et al. (2024)](https://www.jstage.jst.go.jp/article/nmccrj/11/0/11_2024-0098/_html/-char/en)
25. [Kitamura and Kuyama (2022)](https://pubmed.ncbi.nlm.nih.gov/36121607/)
26. [Kozaki et al. (2023)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0282166)
27. [Liao et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper201386.html)
28. [Liclican et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31953125/)
29. [Lv et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8793121/)
30. [Matsunuma et al. (2026)](https://www.jstage.jst.go.jp/article/yakushi/146/2/146_25-00085/_article/-char/en)
31. [Meng et al. (2022)](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2439)
32. [Motomura et al. (2024)](https://academic.oup.com/jjco/article/54/10/1123/7747842)
33. [Nagane et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper198558.html)
34. [Nakagawa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9163585/)
35. [Narita et al. (2021)](https://academic.oup.com/neuro-oncology/article/23/1/122/5862521)
36. [National Cancer Institute Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tirabrutinib)
37. [National Cancer Institute NCI-2021-14196](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-14196)
38. [National Cancer Institute PDQ health professional version](https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq)
39. [National Cancer Institute PDQ patient version](https://www.cancer.gov/types/lymphoma/patient/primary-cns-lymphoma-treatment-pdq)
40. [Nayak et al. (2025a)](https://doi.org/10.1002/hon.70093_88)
41. [Nayak et al. (2025b)](https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v135/8318896)
42. [Nayak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13374761/)
43. [Okawara et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12721748/)
44. [Okita et al. (2021)](https://link.springer.com/article/10.1186/s40164-021-00222-5)
45. [Ono et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13317521/)
46. [ONO Pharma and Deciphera Pharmaceuticals (2025)](https://www.deciphera.com/news/ono-pharma-presents-positive-results-pivotal-trial-us-patients-relapsed-or-refractory-pcnsl-0)
47. [ONO Pharma USA (2023)](https://us.ono-pharma.com/news/tirabrutinib-receives-orphan-drug-designation)
48. [ONO Pharma USA (2025)](https://us.ono-pharma.com/)
49. [Ono Pharmaceutical (2026)](https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/presen/script_20260508_en%5B.pdf)
50. [Ono Pharmaceutical corrected ROSETTA data notice](https://www.ono-ma.jp/tirabrutinib2)
51. [Ono Pharmaceutical corrected ROSETTA real-world progression-free survival figure](https://www.ono-ma.jp/sites/default/files/tirabrutinib/1_T.png)
52. [Ono Pharmaceutical second quarter results presentation script (2026)](https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/presen/script_20261029_en%23.pdf)
53. [PMDA review report (2020)](https://www.pmda.go.jp/files/000237315.pdf)
54. [PMDA revision of precautions (2024)](https://www.pmda.go.jp/files/000269547.pdf)
55. [PROSPECT study website](https://theprospectstudy.com/)
56. [Taiwan Food and Drug Administration assessment report](https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=40103&mid=189&t=s)
57. [Tan et al. (2025)](https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.70083)
58. [University of California, Irvine](https://clinicaltrials.icts.uci.edu/trial/NCT07104032)
59. [Wang et al. (2025)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1559056/full)
60. [Yamasaki et al. (2025a)](https://academic.oup.com/neuro-oncology/article/27/Supplement_3/iii157/8272092)
61. [Yamasaki et al. (2025b)](https://academic.oup.com/neuro-oncology/article/27/Supplement_5/v128/8318850)
62. [Yashima et al. (2026)](https://academic.oup.com/ajhp/advance-article/doi/10.1093/ajhp/zxag190/8711514)
63. [Yasu et al. (2026)](https://www.spandidos-publications.com/10.3892/ol.2026.15531)
64. [Yonezawa et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11059299/)
65. [Yoshioka et al. (2021)](https://link.springer.com/article/10.1007/s13691-021-00491-1)
66. [Yoshioka et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35896257/)
67. [Zhang et al. (2024)](https://doi.org/10.3390/cancers16050860)

## Related pages
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Terms and abbreviations](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations.md)
- [Tirabrutinib: Primary central nervous system lymphoma](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/executive-summary.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Product information and disease description](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Clinical evidence](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: Economic information and modeling report](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economics.md)
- [Tirabrutinib in Primary central nervous system lymphoma: prevalence by geography](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/prevalence.md)
- [Tirabrutinib in Primary central nervous system lymphoma: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/cost-effectiveness-analyses.md)
